Annexon Biosciences: ANX005 Antibody Shines in Phase 3 Trials For Treatment Of Guillain-Barré Syndrome
ANX005 led to significant reductions in GBS-associated disability, improved muscle power, reduced nerve damage, and a reduced need for mechanical ...

![Nanoparticle delivery of aurora kinase inhibitor may improve tumor treatment [PreClinical]](https://www.2minutemedicine.com/wp-content/uploads/2016/02/20541_lores-350x250.jpg)

